All In Biotech

NDA 207501 · Astellas

Cresemba

Isavuconazonium Sulfate · Intravenous

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Mar 6, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

11

2 Phase 3, 0 recruiting

FAERS reports

3,844

2,685 serious, 770 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 25, 2025.

CRESEMBA ® is an azole antifungal indicated for the treatment of: Invasive aspergillosis ( 1.1 ) and Invasive mucormycosis ( 1.2 ) as follows: • CRESEMBA for injection : adults and pediatric patients 1 year of age and older • CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater 1.1 Invasive Aspergillosis CRESEMBA ® is indicated for the treatment of invasive aspergillosis as follows: CRESEMBA for injection : adults and pediatric patients 1 year of age and older [see Clinical Studies ( 14.1 ) and Clinical Pharmacology ( 12.4 )] CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater [see Dosage and Administration ( 2.3 ) Clinical Studies ( 14.1 ) and Clinical Pharmacology ( 12.4 )] 1.2 Invasive Mucormycosis CRESEMBA is indicated for the treatment of invasive mucormycosis as follows: CRESEMBA for injection : adults and pediatric patients 1 year of age and older [see Clinical Studies ( 14.1 ) and Clinical Pharmacology ( 12.3 , 12.4 )] CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kg and greater [see Dosage and Administration ( 2.3 )], Clinical Studies ( 14.1 ) and Clinical Pharmacology ( 12.3 , 12.4 )] 1.3 Usage Specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s) should be obtained prior to initiating antifungal therapy. Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.

Mechanism: Isavuconazonium sulfate is the prodrug of isavuconazole, an azole antifungal [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 8, 2023 Supplement 13 · Efficacy · priority review OrphanLetterLabel
  • Mar 6, 2015 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelSummary ReviewLetter
1 products under this application
  • CRESEMBA · ISAVUCONAZONIUM SULFATE 372MG · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Isavuconazonium" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,094
  • death344
  • nausea190
  • drug ineffective173
  • febrile neutropenia151
  • pyrexia150
  • pneumonia142
  • condition aggravated136
  • fatigue127
  • diarrhoea114
  • dyspnoea109
  • product use in unapproved indication106

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201557
2016250
2017575
2018238
2019269
2020269
2021208
2022250
2023253
2024364
2025520
2026591

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cresemba* (Isavuconazonium Sulfate)

2024 spending

$123M

Beneficiaries

4,665

19,216 claims

Per beneficiary

$26,374

$107.62 per unit

View as table
YearSpending
2020$55,590,672
2021$59,881,233
2022$72,575,256
2023$95,684,253
2024$123,034,269

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 21 on PubMed

Sponsor: Astellas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.